News

October 26 - NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors

Read more

September 8 - Exelixis and NBE-Therapeutics Enter into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Read more

August 10 - NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors

Read more

August 3 - NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer

Read more

January 10 - NBE-Therapeutics closes a USD 22M Series C financing round

Read more